tirzepatide shortage update today FDA says this weight loss drug is over, but patients worry about cost and availability Lilly's weight-loss drug removed from

Initially approved by the FDA for the treatment of type 2 diabetes, they have since also transformed the therapeutic landscape of obesity and weight management

Feng P, Zhang X, Li D, J C, Yuan Z, Wang R, et al

The goal is primarily therapeutic, not experimental

Cronin, M

Similar patterns of weight regain have been observed after stopping liraglutide, another GLP-1 receptor agonist, and continued exercise, especially weight-bearing activities, is recommended to help prevent rebound weight gain

Participants continued standard cholesterol medications without adjustment, though some patients saw enough improvement that their prescribers reduced statin doses